English
Regional settings| Spread | 0.05 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | -0.026179% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | 0.003957% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | USD | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | United States of America | ||||
| Commission on trade1 | 0% |
Information_provided_by_capital
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 2.04 |
| Open | 2.01 |
| 1-Year Change | -26.37% |
| Day's Range | 1.96 - 2.01 |
Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on utilizing its genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure. It is developing a portfolio of product candidates in a variety of indications based on its core platforms, including its non-viral piggyBac DNA Delivery System, Cas-CLOVER site-specific gene editing system and nanoparticle- and AAV-based gene delivery technologies. The Company's product candidate portfolio includes P-BCMA-101, P-PSMA-101, P-BCMA-ALLO1, P-MUC1C-ALL01, Dual CAR, P-OTC-101 and P-MMUT-101. Its lead product candidate, P-BCMA-101, is an autologous CAR-T targeting B cell maturation antigen (BCMA). P-PSMA-101 is an autologous CAR-T product candidate targeting prostate-specific membrane antigen (PSMA), being developed to treat patients with metastatic castrate resistant prostate cancer (mCRPC).
BRIEF: For the fiscal year ended 31 December 2021, Poseida Therapeutics Inc revenues increased from $0K to $31.2M. Net loss decreased 4% to $125M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Interest expense decrease of 4% to $3.4M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$2.10 to -$2.01.
